Earnings summaries and quarterly performance for NovoCure.
Executive leadership at NovoCure.
Board of directors at NovoCure.
AO
Allyson Ocean
Detailed
Director
AD
Asaf Danziger
Detailed
Director
DH
David Hung
Detailed
Director
JH
Jeryl Hilleman
Detailed
Director
KG
Kinyip Gabriel Leung
Detailed
Director
KS
Kristin Stafford
Detailed
Director
MM
Martin Madden
Detailed
Director
TS
Timothy Scannell
Detailed
Director
WV
William Vernon
Detailed
Lead Independent Director
Research analysts who have asked questions during NovoCure earnings calls.
Emily Bodnar
H.C. Wainwright & Co.
6 questions for NVCR
Also covers: AGEN, AGIO, ATOS +7 more
Jason Bednar
Piper Sandler Companies
6 questions for NVCR
Also covers: ALGN, COO, EDAP +17 more
JC
Jonathan Chang
Leerink Partners
4 questions for NVCR
Also covers: ADAP, GMAB, IMCR +10 more
JF
Jessica Fye
JPMorgan Chase & Co.
3 questions for NVCR
Also covers: ALKS, ALNY, AMRN +23 more
Vijay Kumar
Evercore ISI
3 questions for NVCR
Also covers: A, ABT, AVTR +23 more
AA
Albert Agustinus
Leerink Partners
2 questions for NVCR
Also covers: IMCR, KPTI, RVMD
Kevin
Alliance Global Partners
2 questions for NVCR
Also covers: AMLX, CODA, DE
L
Lee
Wells Fargo
2 questions for NVCR
Also covers: BLCO
LH
Lei Huang
Wells Fargo
2 questions for NVCR
Also covers: PEN, RXST, SOLV
KD
Kevin DeGeeter
Ladenburg Thalmann & Co. Inc.
1 question for NVCR
Also covers: IDXG, ORIC, RVMD +2 more
KJ
Kevin Joaquin
Evercore ISI
1 question for NVCR
Also covers: HOLX
LB
Larry Biegelsen
Wells Fargo & Company
1 question for NVCR
Also covers: ABT, ALC, AXNX +25 more
LB
Lawrence Biegelsen
Wells Fargo
1 question for NVCR
Also covers: ABT, ALC, BAX +16 more
NS
Na Sun
JPMorgan Chase & Co.
1 question for NVCR
Also covers: HALO
Recent press releases and 8-K filings for NVCR.
Novocure Discusses Strategic Shift, 2026 Revenue Guidance, and Pancreatic Cancer Launch
NVCR
CEO Change
Guidance Update
Product Launch
- Frank Leonard took over as CEO in December, emphasizing a strategic shift to ensure clinical developments translate into viable businesses and widespread patient use.
- Novocure provided 2026 revenue guidance of $675 million - $705 million, primarily driven by Glioblastoma (GBM).
- In 2025, GBM generated approximately $645 million in revenue from 4,400+ active patients. The company anticipates low- to mid-single digit growth in GBM for 2026 , with the TRIDENT study (top-line data expected in Q2 2026) potentially expanding the eligible patient population by 25%.
- The company has launched Optune Pax for locally advanced pancreatic cancer, targeting an estimated Total Addressable Market (TAM) of approximately 15,000 patients a year, which is about 50% larger than GBM. New indications are projected to contribute $15 million - $25 million to revenue in 2026.
- Novocure aims to achieve profitability over the next 2-3 years through continued revenue growth from GBM and pancreatic cancer, coupled with increased discipline in operating and R&D expenditures.
1 day ago
Novocure Discusses Strategic Shift, Financial Outlook, and Clinical Milestones
NVCR
CEO Change
Guidance Update
Product Launch
- Frank Leonard took over as CEO in December, emphasizing a strategic shift towards ensuring clinical development translates into commercially viable products and successful patient use.
- Novocure reported $645 million in GBM revenue for 2025 and projects low- to mid-single digit growth in GBM for the current year, with a 40% penetration rate in established markets.
- The company provided 2026 revenue guidance of $675 million to $705 million, anticipating $15 million to $25 million from new indications (including pancreatic cancer) in 2026, up from $10 million in 2025.
- Key clinical milestones include the TRIDENT study for newly diagnosed glioblastoma, with top-line data expected in Q2, which could expand the eligible patient population by 25%.
- Novocure aims to achieve profitability within the next two to three years through continued revenue growth and increased discipline in operating and R&D spending.
1 day ago
Novocure CEO Outlines Strategic Focus and 2026 Revenue Guidance
NVCR
CEO Change
Guidance Update
Product Launch
- Frank Leonard, who became CEO in December, is focusing Novocure's strategy on ensuring clinical developments translate into viable businesses and increasing discipline in clinical development and commercial operations. The company will prioritize indications with low drug bioavailability and/or the ability to leverage immune response upregulation, as well as highly motivated and healthy patients.
- In Glioblastoma (GBM), Novocure reported $645 million in revenue in 2025 and expects low- to mid-single digit growth in 2026. The TRIDENT study for newly diagnosed GBM, which could expand the eligible patient population by 25%, is expected to provide top-line data in Q2 2026. For pancreatic cancer, where Optune Pax is approved for locally advanced cases, the total addressable market is estimated at 15,000 patients/year, approximately 50% larger than GBM. The PANOVA-4 phase 2 trial in metastatic pancreatic cancer is expected to read out in the coming weeks.
- Novocure expects total revenue of $675 million - $705 million in 2026, with $15 million - $25 million from new indications (up from $10 million in 2025). The company aims for a path to profitability over the next 2-3 years through revenue growth and increased discipline in operating expenses, particularly R&D.
1 day ago
Novocure's Optune Lua Receives Reimbursement Approval in Japan
NVCR
Product Launch
New Projects/Investments
- Japan's Ministry of Health, Labour and Welfare has approved reimbursement for Novocure’s Optune Lua under the National Health Insurance, providing coverage for eligible patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC).
- This approval is a significant step in Novocure’s international expansion, expected to increase access to the noninvasive therapy in Japan, where an estimated 100,000 patients are diagnosed with NSCLC annually.
- Despite this commercial opportunity, Novocure, a $1.53 billion market-cap oncology device company with $642 million in revenue, faces financial challenges including negative operating and net margins, a high debt-to-equity ratio of approximately 2.34, and an Altman Z-Score near 0.08, indicating significant financial and bankruptcy risk.
Mar 2, 2026, 12:13 PM
Novocure Receives Reimbursement Approval for Optune Lua in Japan
NVCR
Product Launch
New Projects/Investments
- Novocure announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.
- This approval enables Novocure to launch Optune Lua in Japan for the treatment of non-small cell lung cancer (NSCLC).
- Optune Lua is approved for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who have progressed on or after platinum-based chemotherapy.
- Approximately 100,000 patients are diagnosed with NSCLC each year in Japan, highlighting the significant patient population for this treatment option.
Mar 2, 2026, 12:00 PM
NovoCure Announces Q4 and Full Year 2025 Results and 2026 Guidance
NVCR
Earnings
Guidance Update
Product Launch
- NovoCure reported net revenues of $174.4 million for Q4 2025 and $655.4 million for the full year 2025, with a net loss of $(24.5) million in Q4 2025 and $(136.2) million for the full year 2025.
- The company provided fiscal year 2026 guidance, projecting net revenue between $675 million and $705 million and Adjusted EBITDA between $(20 million) and $0 million.
- Key commercial catalysts for 2026 include the U.S. launch of Optune Pax for pancreatic cancer in Q1 and Optune Mya for brain metastases from NSCLC in Q4.
- Clinical milestones for 2026 include the release of topline data from the Phase 2 PANOVA-4 trial (met. pancreatic cancer) in Q1 and the Phase 3 TRIDENT trial (GBM) in Q2.
Feb 26, 2026, 1:00 PM
Novocure Reports Record 2025 Revenue, Issues 2026 Guidance, and Receives Optune Pax Approval
NVCR
Earnings
Guidance Update
Product Launch
- Novocure reported record net revenue of $655 million for full-year 2025, an 8% increase from 2024, with a net loss of $136 million and negative adjusted EBITDA of $34 million.
- The company issued 2026 net revenue guidance of $675 million-$705 million (representing 3%-8% year-over-year growth) and adjusted EBITDA guidance of -$20 million to break even, reflecting an accelerated path to profitability.
- Novocure received FDA approval for Optune Pax for locally advanced pancreatic cancer on February 11th, and successfully resolved a Medicare billing issue with privileges reinstated retroactively to December 17th, 2025, with no expected negative impact on revenue.
Feb 26, 2026, 1:00 PM
Novocure Reports Record 2025 Revenue, Issues 2026 Guidance, and Receives FDA Approval for Optune Pax
NVCR
Earnings
Guidance Update
Product Launch
- Novocure reported record net revenues of $655 million for the full year 2025, an 8% increase from 2024, and a net loss of $136 million.
- The company provided 2026 net revenue guidance of $675 million to $705 million (representing 3% to 8% year-over-year growth) and adjusted EBITDA guidance of -$20 million to break even.
- The FDA approved Optune Pax for locally advanced pancreatic cancer on February 11th, with launches planned for the U.S. and Germany, leveraging the existing torso sales force.
- Key clinical trial readouts are anticipated in 2026, including PANOVA-4 (Phase 2 pancreatic cancer) next month and TRIDENT (Phase 3 GBM) in Q2.
- Novocure resolved a Medicare billing issue, with CMS reinstating billing privileges retroactively to December 17, 2025, and no expected negative impact on revenue.
Feb 26, 2026, 1:00 PM
Novocure Reports Record 2025 Revenue, Issues 2026 Guidance, and Announces Optune Pax Approval
NVCR
Earnings
Guidance Update
Product Launch
- Novocure reported record net revenues of $655 million for the full year 2025, an 8% increase from 2024, with Q4 2025 net revenue at $174 million. The full-year net loss was $136 million, and adjusted EBITDA was negative $34 million.
- For 2026, the company provided annual net revenue guidance of $675 million-$705 million (3%-8% year-over-year growth) and adjusted EBITDA guidance of -$20 million to break even, signaling an accelerated path to profitability.
- Novocure received FDA approval for Optune Pax for locally advanced pancreatic cancer on February 11, 2026, and has commenced its launch, with regulatory filings also submitted in Europe and Japan.
- Frank Leonard assumed the CEO role, and Dr. Uri Weinberg was appointed Chief Medical Officer in addition to his Chief Innovation Officer role, combining scientific and clinical organizations to accelerate R&D execution.
- A Medicare billing issue was resolved with CMS reinstating billing privileges retroactively to December 17, 2025, with no expected negative impact on revenue recognition.
Feb 26, 2026, 1:00 PM
Novocure Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance
NVCR
Earnings
Guidance Update
Product Launch
- Novocure reported full year 2025 net revenues of $655 million and Q4 2025 net revenues of $174 million, with a Q4 net loss of $24.5 million and Adjusted EBITDA of $(16.4) million. The company held $447.7 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
- The U.S. FDA approved Optune Pax for the treatment of locally advanced pancreatic cancer in February 2026.
- Novocure provided 2026 financial guidance, projecting total net revenues between $675 million and $705 million and Adjusted EBITDA between $(20) million and $0 million.
- As of December 31, 2025, there were 4,620 total active patients on TTFields therapy globally. Additionally, Novocure's CMS billing privileges were reinstated retroactively to December 17, 2025, with no anticipated impact on revenue recognition.
Feb 26, 2026, 12:01 PM
Quarterly earnings call transcripts for NovoCure.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more